Medivation Company Profile

Aggregated data from the web about Medivation

Company Name	Medivation
Website	medivation.com
Snippet	Medivation is an American biopharmaceutical company focused on rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation, in collaboration with Astellas, is currently developing enzalutamide for multiple stages of prostate cancer and for breast cancer. On August 31, 2012, Medivation and Astellas announced that the U.S. Food and Drug Administration (FDA) granted approval to XTANDI (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI is an oral, once-daily androgen receptor inhibitor.[1] Medivation is headquartered in San Francisco, California, and it began operations in December 2004 with the acquisition of Medivation Neurology, Inc.[2] The current CEO is David Hung.[3]
Owner	Pfizer
Country	united states
Founded	2004
Website	medivation.com
Industry	Pharmaceutical industry
linkedin	linkedin.com/company/medivation
Key people	David Hung
size_range	201 - 500
Headquarters	San Francisco, California, United States
Number of employees	173

Medivation is part of the United States company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.